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Abstract
Background Omega-loop gastric bypass (OLGB) results in
weight loss (WL) but data on its impact on liver and glucose
metabolism compared to Roux-en-Y gastric bypass (RYGB)
is lacking. Therefore, the aim of this study was to compare the
development of hepatic and metabolic markers as well as WL
between the above-mentioned surgical groups during the first
postoperative year.
Methods We retrospectively evaluated the respective parame-
ters in non-diabetic morbidly obese patients who underwent
either RYGB (n=25) or OLGB (n=25).
Results Compared to RYGB, OLGB showed a greater WL
percentage. Liver transaminases dropped in RYGB, while
rose in OLGB. No correlation between aspartate
transaminase, alanine transaminase, and WL could be detect-
ed. Gamma-glutamyltransferase decreased significantly in
RYGB over the first 3 months, while it increased in OLGB.
We found higher levels of triglycerides, insulin, homeostasis
model assessment of insulin resistance (HOMA2-IR), and liv-
er fat percentage in RYGB at baseline, despite matching the
groups for age, sex, and BMI. Those differences disappeared,
except for triglycerides, within 1 year. All metabolic parame-
ters correlated with WL.
Conclusion OLGB results in greater WL but transiently
deteriorated several liver parameters in the first postop-
erative year. This was not associated with WL. The
impact of these results on hepatic outcomes such as
non-alcoholic steatohepatitis and fibrosis progression
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requires further studies. In both groups, improved insu-
lin resistance and sensitivity were correlated with higher
WL and lower liver fat percentage, respectively.
Keywords Gastric bypass . Morbid obesity . Liver
parameters . Metabolic parameters .Weight loss
Introduction/Purpose
Bariatric surgery is the most successful treatment of morbid
obesity [1] since it is associated with effective long-term
weight loss (WL) and decreases overall mortality [2]. At pres-
ent, three categories of bariatric procedures are in use: (a)
purely gastric restriction (e.g., gastric banding, sleeve gastrec-
tomy); (b) gastric restriction with a mild malabsorptive effect,
represented by Roux-en-Y gastric bypass and omega-loop
gastric bypass; and (c) gastric restriction with an extensive
malabsorptive effect such as the biliopancreatic diversion
[3]. The extent of WL is in part related to the complexity of
the bariatric procedure [4]. A small number of studies have
compared the results of Roux-en-Y gastric bypass, which is
still the gold standard for many bariatric teams [5], and
omega-loop gastric bypass. Regarding previous data, it be-
came evident that omega-loop gastric bypass is a bariatric
procedure that demonstrates initial promising results in terms
of WL, feasibility, and safety [6, 7]. However, little is known
about the short- and long-term impact of this procedure, espe-
cially in terms of its impact on liver function and glucose
metabolism.
Several studies investigating the effect of bariatric surgery
on liver enzymes and non-alcoholic fatty liver disease
(NAFLD) have shown an improvement of serum transami-
nases and hepatic histologic features after surgery [8–11].
From previous data, however, it became evident that rapid
WL, as seen with bariatric surgery, can also adversely affect
the liver [11]. Moreover, several case reports of patients with
early hepatic failure after bariatric surgery are described in the
literature [12–14].
The aim of this evaluation was to provide data on the de-
velopment of hepatic and metabolic markers as well as onWL
in morbidly obese patients undergoing either Roux-en-Y gas-
tric bypass or omega-loop gastric bypass during the first 12




For this investigation, we accomplished an analysis within the
cohort study considering all consecutive bariatric patients in
the outpatient clinic of the Division of Endocrinology and
Metabolism in the General Hospital Vienna. The procedures
used in this study were in accordance with the Declaration of
Helsinki [15] and were approved and registered (no. 988/
2011) by the Ethics Committee of the Medical University of
Vienna. All participants provided their written informed con-
sent prior to the study. A multidisciplinary team performed a
combined workup to ensure that potential surgical candidates
met the criteria for bariatric surgery [16]. The exclusion
criteria were as follows: diabetes, earlier bariatric surgery,
active malignancy during the past 5 years, myocardial
infarction during the past 6 months, eating disorders, psy-
chiatric problems contraindicating bariatric surgery, regu-
lar use of cortisone, alcohol (>20 g/day men, >10 g/day
women) or drug abuse, and other severe illnesses. Daily
alcohol consumption was evaluated during the preopera-
tive dietary counseling on basis of the self-reported nutri-
tional protocols.
Patients
From February 2011 to February 2013, a total of 86 patients
underwent omega-loop gastric bypass [17]. Due to results on
preliminary data that showed significant differences between
diabetic and non-diabetic subjects [18], diabetic patients
(n=22) were not included in this analysis. In order to ade-
quately compare the available data on omega-loop gastric
bypass to the Roux-en-Y gastric bypass procedure, we
matched patients by age, gender, and initial body mass index
(BMI). Moreover, 36 patients with missing preoperative liv-
er data and 3 with no adequate Roux-en-Y gastric bypass
matches were excluded from the current analysis. Non-dia-
betic subjects who underwent either Roux-en-Y gastric by-
pass (n=25, female=92 %, 44.6±10.3a, 125±18 kg, BMI
45.6 ± 4.1) or omega-loop gastric bypass (n = 25,
male = 88 %, 43.8 ± 13.1a, 128 ± 24 kg, BMI 45.3 ± 5.3)
were analyzed. Baseline data are presented in Table 1 and
Figs. 1, 2, 3, and 4.
Surgical Technique
All procedures were performed by the same surgical team
using a laparoscopic approach. Roux-en-Y gastric bypass con-
sists of a longitudinal 30-ml gastric pouch which is anasto-
mosed end-to-side with the jejunal limb and a latero-lateral
jejuno-jejunal anastomosis resulting in a biliopancreatic limb
of approximately 80 cm and an alimentary limb of approxi-
mately 150 cm [5]. Omega-loop gastric bypass is a simplified
procedure that consists of a unique gastrojejunal anastomosis
between a 30–40-ml sleeve gastric pouch and a jejunal omega
loop of 200 cm [5, 19].
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Follow-Up
All patients were followed up before surgery (T0) (on average
2 months), 3 (T3), 6 (T6), and 12 (T12) months postoperative-
ly. Medical treatment was adjusted according to the current
needs of the patient. Postoperatively, supplements were pre-
scribed with respect to the available guidelines at that time [3].
Variables
Following blood parameters were evaluated: total protein, al-
bumin, total bilirubin, alkaline phosphatase (AP), aspartate
transaminase (AST), alanine transaminase (ALT), gamma-
glutamyltransferase (GGT), triglycerides (TG), prothrombin
time, platelets, glucose, insulin, and high-sensitive C-reactive
protein (hsCRP) as marker for tissue damage, infection, inflam-
mation, and malignant neoplasia [20]. The NAFLD liver fat
score [21], a test to accurately predict non-alcoholic fatty liver
disease (NAFLD), liver fat percentage (%) [21], based on
fasting glucose, fasting insulin, De Ritis ratio, the presence of
metabolic syndrome and type 2 diabetes, and the NAFLD fi-
brosis score [22], a scoring system consisting of BMI, age,
glycemic status, platelet count, albumin level, and De Ritis ratio
[22] to separate NAFLD patients with and without advanced
fibrosis were calculated. Furthermore, De Ritis ratio, as a mark-
er for severe liver damage [23], as well as homeostasis model
assessment of insulin resistance (HOMA2-IR) and quantitative
insulin sensitivity check index (QUICKI) [24], as marker for
insulin sensitivity, were computed. The presence of metabolic
syndrome was defined according to criteria of the International
Diabetes Federation [25]. Abnormal liver parameters were de-
fined as an elevation of ALT, and/or AST, and/or GGT levels
above the upper limit of normal (ULN) [26]. In order to discuss
the clinical relevance of any findings, there was a separate anal-
ysis with values >2× ULN and the proportion of results out of
the normal range. Age, height, weight, and BMI were deter-
mined. Due to the different WL reporting methods in previous
studies, we decided to calculate all of the recommended ones
[27] to allow easier comparison of the data.
Statistical Analysis
Statistical calculations were performed by SPSS 20.0 (SPSS
Inc, Chicago, IL). Data are shown as means and standard devi-
ations (SD). The hypothesis of variables being normally distrib-
uted was tested by Kolmogorov-Smirnov test. Differences in
the distributions of variables between Roux-en-Y gastric by-
pass and omega-loop gastric bypass were tested by a
Student’s t test, respectively, by Mann-Whitney U test for two
independent samples. We used repeated-measures ANOVA,
using random error (linear mixed model) to assess the effect
of time and the interaction for changes in laboratory parameters
between the groups, by using different covariance structure
models as appropriate and adjusted for baseline values, age,
and sex. Moreover, a post hoc analysis with Bonferroni correc-
tion was used. Binary logistic regression was used to estimate
the odds for type of surgery. Linear regression was used to
identify independent variables (e.g., age, gender, preoperative
BMI) associated with changes in the evaluated parameters.
Spearman’s and Pearson’s correlation coefficients were used
to determine associations between changes in relevant parame-
ters. The chi-square test was applied to control whether there
are significant differences between the expected and the ob-
served frequencies in categorical liver, cholestatic, and meta-
bolic parameters. Means were compared unadjusted without
imputation of missing data. Statistical significance for all anal-
yses was assumed as p≤0.05.
Results
Liver Function
For AST, a significant group and time difference could be
found. ALT dropped in Roux-en-Y gastric bypass, while ris-
ing in omega-loop gastric bypass with a significant group and
time difference. Moreover, a positive correlation could be
found between ALT, surgical method (r=0.406, p=0.006)
and De Ritis ratio >1 (r=0.451, p=0.002) at T12. Notably,
no correlation between WL, ALT, and AST was observed.
These parameters remained in the normal range in both groups
(Fig. 1).
Initially, Omega-loop gastric bypass group showed a sig-
nificant higher count in platelets, this difference disappeared
at T3. Nevertheless, a difference between the groups (Table 1),
as well as a negative correlation with WL (r = −0.346,
p=0.002) could be detected.
A significant group and time interaction could be found for
prothrombin time (Table 1) as well as a significant increasing
proportion of low prothrombin time in omega-loop gastric
bypass at T3 (Roux-en-Y gastric bypass vs. omega-loop gas-
tric bypass; T0: 8 vs. 0 %, n.s.; T3: 5 vs. 8 %, p<0.05). A
negative correlation between prothrombin time and WL was
found in omega-loop gastric bypass (r=−0.543, p<0.001).
No differences appeared in the course of albumin, while
protein diminished significantly over time and group (Fig. 2).
A negative correlation between protein and WL in both
groups (r=−0.428, p<0.001), as well as for albumin and
hsCRP (r=−0.611, p<0.01) in omega-loop gastric bypass at
T6 was found.
Cholestatic Parameters
In Roux-en-Y gastric bypass, GGT significantly decreased by
nearly half of the initial value, while it remained stable in
omega-loop gastric bypass and a significant group and time
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difference could be found (Table 1). Younger patients
(<50 years) had a greater chance of lower GGT quartiles over
time (odds ratio (OR) 0.52; 95 % confidence interval
(CI)=0.36–0.75; p<0.001; adjusted for initial BMI). A neg-
ative correlation between GGT and WL could be seen in
Roux-en-Y gastric bypass (r=−0.571, p<0.001).
In the whole cohort, a maximum rise in bilirubin and AP
was found at T3. The values of both remained in the high–
normal range until T12 (Fig. 3).
Calculated Liver Scores
NAFLD liver fat score showed a significant higher proportion
of NAFLD in Roux-en-Y gastric bypass until T6 (T0: Roux-
en-Y gastric bypass 75 % vs. omega-loop gastric bypass 6 %,
p<0.001; T3: 57 vs. 8 %, p<0.01; T6: 13 vs. 5 %, n.s.; T12: 0
vs. 13 %, n.s.).
Liver fat percentage showed a similar development with a
significant difference over time (Table 1). Over the whole
observation period, a strong correlation could be found be-
tween liver fat percentage and HOMA2-IR (r = 0.616,
p<0.001); QUICKI (r=−0.623 p<0.001); AST (r=0.506,
p < 0.001); ALT (r = 0.429, p < 0.001); and TG (T0:
r=0.519, p<0.001) in both groups.
Omega-loop gastric bypass showed a significant higherDe
Ritis ratio at T12 (Table 1) and a significant group and time
interaction could be detected. Subsequently, at T12, 54 % in
Roux-en-Y gastric bypass vs. 90 % in the omega-loop gastric
bypass (p<0.01) had a De Ritis ratio ≥1. Over the observation
period, no differences were found in the distribution of indi-
viduals with, without, and undefined status of liver fibrosis
calculated by NAFLD fibrosis score.
Metabolic Markers
Glucose significantly decreased in both groups until T12.
Insulin was significantly higher in Roux-en-Y gastric bypass
at T0, although no group and time interaction could be found.
Fig. 1 Pre- and postoperative
mean protein and albumin levels
in patients with Roux-en-Y gas-
tric bypass (marked by a full line)
and omega-loop gastric bypass
(marked by a dotted line).aT test
comparing Roux-en-Y gastric
bypass and omega-loop gastric
bypass at baseline (T0), 3 (T3), 6
(T6), and 12 (T12) months.
Linear mixed model (LMM),
adjusted for baseline values, sex,
and age for changes over btime
course, cbetween groups, and
dchanges over time course and
between groups. *p < 0.05;
**p< 0.01; ***p< 0.001;
n.s. not significant
Fig. 2 Pre- and postoperative
mean AST and ALT levels in
patients with Roux-en-Y gastric
bypass (marked by a full line) and
omega-loop gastric bypass
(marked by a dotted line). aT test
comparing Roux-en-Y gastric
bypass and omega-loop gastric
bypass at baseline (T0), 3 (T3), 6
(T6), and 12 (T12) months.
Linear mixed model (LMM),
adjusted for baseline values, sex,
and age for changes over btime
course, cbetween groups, and
dchanges over time course and
between groups. *p < 0.05;
**p< 0.01; ***p< 0.001;
n.s. not significant
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We observed a significant group difference for HOMA2-IR
from T0 to T6 and a significant group and time effect (Fig. 4),
whereby values were higher in Roux-en-Y gastric bypass.
QUICKI was significantly higher in omega-loop gastric by-
pass patients at T3, T6, and T12; however, no group and time
interaction could be detected (Fig. 4).
TG showed a significant reduction over time in both
groups. Worth mentioning is a significant initial increase of
TG in omega-loop gastric bypass, which finally ended up in a
greater reduction. For all above-mentioned metabolic
markers, a negative, respectively, for QUICKI positive, corre-
lation with WL in both groups could be seen (glucose:
r = −0.451, p < 0.001; insulin: r = −0.379, p < 0.001;
HOMA2-IR: r = −0.520, p < 0.001; QUICKI: r = 0.540,
p<0.001; TG: r=−0.418, p<0.001).
hsCRP showed a reduction over time with lowest levels in
both groups at T12. Notable correlations were found withWL
(r=−0.293, p<0.001) over time in both groups, respectively.
AST (r = 0.527, p < 0.001); AST >2× ULN (r = 0.501,
p = 0.001); ALT (r = 0.358, p = 0.02); ALT >2× ULN
(r=0.488, p<0.01); and glucose (r=0.474, p<0.01), in both
groups at T0.
Weight Loss
WL (mean±SD) was 30±9 vs. 38±7 % (%BMI loss), which
equals a percentage excess WL (%EWL) of 94±36 vs. 127
±31 % or percentage excess BMI loss (%EBMIL) of 67±22
vs. 88±16 % in Roux-en-Y gastric bypass vs. omega-loop
gastric bypass after 12 months. Using the binary logistic re-
gression, an increased chance for greater WL in omega-loop
gastric bypass was shown (OR=1.19; 95 % CI=1.11–1.27;
p<0.001).
Fig. 3 Pre- and postoperative
mean bilirubin and alkaline
phosphatase levels in patients
with Roux-en-Y gastric bypass
(marked by a full line) and
omega-loop gastric bypass
(marked by a dotted line). aT Test
comparing Roux-en-Y gastric
bypass and omega-loop gastric
bypass at baseline (T0), 3 (T3), 6
(T6), and 12 (T12) months.
Linear mixed model (LMM), ad-
justed for baseline values, sex,
and age for changes over btime
course, cbetween groups, and
dchanges over time course and
between groups. *p < 0.05;
**p< 0.01; ***p< 0.001; n.s. not
significant
Fig. 4 Pre- and postoperative
mean HOMA2-IR and QUICKI
levels in patients with Roux-en-Y
gastric bypass (marked by a full
line) and omega-loop gastric by-
pass (marked by a dotted line). aT
test comparing Roux-en-Y gastric
bypass and omega-loop gastric
bypass at baseline (T0), 3 (T3), 6
(T6), and 12 (T12) months.
Linear mixed model (LMM), ad-
justed for baseline values, sex,
and age for changes over btime
course, cbetween groups, and d-
changes over time course and be-
tween groups. *p< 0.05;
**p< 0.01; ***p< 0.001; n.s. not
significant
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Discussion
The superiority of omega-loop gastric bypass over Roux-en-Y
gastric bypass in terms of WL was demonstrated in previous
studies [5, 6], as well as in our study. We did not observe any
influence of gender, age, or preoperative BMI on WL regard-
less of the procedure. Studies reported an EWL percentage
range from 59 to 63 % in Roux-en-Y gastric bypass [5–7,
19, 28–30] and 65 to 89 % in omega-loop gastric bypass [5,
6, 30]. Compared to this data, we observed a larger WL in
both groups. The difference might be explained by differences
in the length of the bypassed small bowel with a differing
malabsorptive effect. In addition to the superior WL in
omega-loop gastric bypass, we might assume additional ben-
eficial effects, as elevated transaminases, cholestatic and met-
abolic parameters improve driven by WL [11, 31, 32].
WL is currently an effective treatment of NAFLD
and non-alcoholic steatohepatitis (NASH) in patients
with obesity [11, 32, 33]. Several studies investigating
the effect of bariatric surgery on liver enzymes and
NAFLD have shown an improvement of serum transam-
inases and hepatic histologic features after surgery
[8–11]. However, so far, no current data is available
for omega-loop gastric bypass and liver status.
Certainly from previous literature, it became evident that
rapid WL after bariatric surgery can also adversely af-
fect the liver [11]. This could be attributed to the al-
ready pre-existing degree of fibrosis which subsequently
worsened by rapid WL due to the bariatric procedure
and/or due to a lack of adequate supplementation of
macro- and micronutrients [11, 34].
In our study, the increase of liver transaminases (ALT,
AST) was greater in omega-loop gastric bypass than in
Roux-en-Y gastric bypass with a maximum rise after
3 months. These findings are comparable with two studies
of Wolf AM et al. [9, 35]. The values of AST and ALT suc-
cessively decreased and finally fell below those of T0 in
Roux-en-Y gastric bypass, whereas both parameters remained
above the preoperative values in omega-loop gastric bypass.
The results remained within the normal range in both groups
and during the whole observation period. Nevertheless, even
slightly increased but still normal aminotransferase concentra-
tions are related to an increased risk of death from liver disease
[36]. Significant liver disease (i.e., bridging fibrosis and cir-
rhosis) may be accompanied by mild transaminase elevations
[37], as seen in our data. GGT, as well as AST, are associated
with higher risk of cardiovascular disease (CVD), particularly
in young individuals [38, 39]. GGT is known as a marker for
sub-clinical inflammation, oxidative stress, visceral, respec-
tively, intrahepatic fat and therefore for insulin resistance
[38]. Our data shows a rapid reduction of GGT in Roux-en-
Y gastric bypass and a temporally delayed one in omega-loop
gastric bypass, especially in younger patients, who might
benefit most from a reduction [39]. Bilirubin and AP were
both increasing after surgery and remained above the baseline
level after 12 months. Moreover, a dependence of bilirubin
and AP with WL could only be seen in Roux-en-Y gastric
bypass. These findings are contrary to previous data [40].
Furthermore, we found a clear positive association between
WL and the improvement of parameters for insulin resistance,
insulin sensitivity and liver fat percentage in both groups.
Interestingly, in comparison to other studies [8, 32], we could
not find a correlation between AST, ALT, and WL.
Noteworthy, the proportion of patients with higher De Ritis
ratio was significantly greater in omega-loop gastric bypass
after 12 months. Furthermore, omega-loop gastric bypass pre-
sented a significantly higher level of ALT, lower level of pro-
tein with a negative correlation with WL, prothrombin time,
and platelets, which are also indicators for liver function [41],
at T12. The transient elevation of liver parameters in patients
after bariatric surgery [11, 34, 35] and during a low-calorie
diet without bariatric surgery [31] were previously described.
Different hypotheses explaining these changes in hepatic and
metabolic parameters exist, whereas it is most likely that the
triggers are multifactorial. Mild and transient changes in liver
histology, which themselves could be induced by the modifi-
cations in liver physiology such as the increased ketone pro-
duction or active mobilization of lipids from adipose tissue
and hepatocytes during calorie restriction resulting in poten-
tially toxic intermediate metabolites such as free fatty acids
and ceramides, could be a key mechanism [31, 42].
Furthermore, rapid mobilization of intra- and extrahepatic fat
stores are probably associated with deficient protein intake
during WL and may contribute to aggravation of pre-
existing liver disease [34]. Moreover, the trauma of surgery
associated with an increase in production of stress hormones,
oxidative stress, and inflammatory responses is associated
with reduced hepatic function [9]. Importantly, we could not
detect a correlation between liver transaminases and WL.
We found higher levels of several metabolic parameters
(insulin, HOMA2-IR, liver fat percentage) at T0 in Roux-en-
Y gastric bypass despite of matching our groups for age, sex,
and BMI. Those differences disappeared at T12, and all of
them were positively correlated with WL. Consequently, both
surgical groups showed a positive metabolic outcome due to
WL.
A limitation of the current report is the small sample size,
due to the restricted availability of non-diabetic omega-loop
gastric bypass data. Nevertheless, this sample is well charac-
terized and the laboratory data is almost complete, which
strengthens our study. The data represents a novelty, because
up to now, to our current knowledge, no study has assessed the
differences in liver, cholestatic, and metabolic parameters in
Roux-en-Y gastric bypass vs. omega-loop gastric bypass.
Another limitation is the lack of liver biopsies, which might
give us better insight into the liver situation preoperatively and
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during the postoperative period. Therefore, we cannot exclude
the presence of relevant liver injury at baseline, which possi-
bly could explain the results in omega-loop gastric bypass at
T12.
In conclusion, omega-loop gastric bypass results in greater
WL and deterioration of liver parameters in the first year after
surgery with no association to WL. It remains unclear what
induces the bimodal alteration in liver transaminases and cho-
lestatic parameters during the early postoperative phase and
also after 12 months. Given the potential for worsening fibro-
sis following bariatric surgery, patients should be monitored
closely and continue to undergo through hepatological work-
up, including non-invasive testing for fibrosis or, even liver
biopsy.More research in this field, including histopathological
data, is needed to define clinical relevance of these findings on
hepatic outcome in terms of deterioration of non-alcoholic
steatohepatitis and fibrosis and to characterize patients at risk.
In both groups, improved outcome in terms of insulin resis-
tance and sensitivity could be found in correlation to higher
WL and lower liver fat percentage, respectively.
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